A galactose‐1‐phosphate uridylyltransferase‐null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue‐specific and longitudinal differences in galactose metabolism-Reference-Cited by-同舟云学术

A galactose‐1‐phosphate uridylyltransferase‐null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue‐specific and longitudinal differences in galactose metabolism

Published:2019-12-29 Issue:3 Volume:43 Page:518-528
ISSN:0141-8955
Container-title:Journal of Inherited Metabolic Disease
language:en
Short-container-title:Jrnl of Inher Metab Disea

Author:

Rasmussen Shauna A.¹,Daenzer Jennifer M. I.¹,MacWilliams Jessica A.¹,Head S. Taylor²,Williams Martine B.¹,Geurts Aron M.³,Schroeder Jason P.¹,Weinshenker David¹,Fridovich‐Keil Judith L.¹^ORCID

Affiliation:

1. Department of Human Genetics Emory University School of Medicine, Emory University Atlanta Georgia

2. Rollins School of Public Health, Graduate Program in Biostatistics Emory University Atlanta Georgia

3. Gene Editing Rat Resource Center Medical College of Wisconsin Milwaukee Wisconsin

Funder

National Institutes of Health

School of Medicine, Emory University

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jimd.12205

Reference28 articles.

1. Biosynthesis and Composition of Milk

2. International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up

3. The natural history of classic galactosemia: lessons from the GalNet registry

4. Presentation, progression, and predictors of ovarian insufficiency in classic galactosemia

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Galactose-1-phosphate inhibits cytochrome c oxidase and causes mitochondrial dysfunction in classic galactosemia;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Phenotypic and genetic spectra of galactose mutarotase deficiency: A nationwide survey conducted in Japan;Genetics in Medicine;2024-08

3. Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study;The Journal of Clinical Pharmacology;2024-07-10

4. Deep postnatal phenotyping of a new mouse model of nonketotic hyperglycinemia;Journal of Inherited Metabolic Disease;2024-06-05

5. Deep postnatal phenotyping of a new mouse model of nonketotic hyperglycinemia;2024-03-29